Trial Profile
A Phase 1 Study of IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 30 Oct 2023 Status changed from active, no longer recruiting to completed.
- 04 Apr 2023 Results assessing safety and efficacy of Ivosidenib as maintenance in patients with acute myeloid leukemia, published in the Clinical Cancer Research.
- 25 Oct 2021 Planned End Date changed from 31 Jul 2024 to 31 Dec 2025.